Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
Cumberland ended the quarter with approximately
"We have had a strong first half of the year, especially following the progress of our clinical development programs," said
RECENT COMPANY DEVELOPMENTS INCLUDE:
Vibativ® 4-Vial Starter Pak Now Available for Vizient Providers
Cumberland recently announced the availability of the Vibativ (telavancin) 4-Vial Starter Pak through a new supply arrangement with
As the country's largest provider-driven health care performance improvement company,
Pharmacokinetic Analysis Reinforces Vibativ Dosing Strategies
A comprehensive new pharmacokinetic analysis of Vibativ was published in Antimicrobial Agents and Chemotherapy in
Ifetroban Clinical Studies
In
The top-line FIGHT DMD study findings were also selected for a late-breaking presentation at the
Meanwhile, Cumberland has been evaluating its ifetroban product candidate in a
In addition, Cumberland has a
New Study Features Caldolor® (ibuprofen injection) for Older Patients
In
FINANCIAL RESULTS:
Net Revenue: For the second quarter of 2025, net revenues were
Year-to-date 2025 net revenues were
Operating Expenses: Total operating expenses were
Net Income (loss): Year-to-date net income was approximately
Adjusted Earnings: Adjusted earnings for the six months ended 2025 were
Balance Sheet: At
EARNINGS REPORT CALL:
A conference call will be held today,
The link to register is https://register-conf.media-server.com/register/BI0e0cfee6a381408fa7d3d939d82dfa04.
Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting:https://edge.media-server.com/mmc/p/zpxz72fn.
ABOUT
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has a series of
For more information on Cumberland's approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company's website at www.cumberlandpharma.com.
About Acetadote® (acetylcysteine) Injection
Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in
About Caldolor® (ibuprofen) Injection
Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever.
Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com.
About Kristalose® (lactulose) Oral Solution
Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit www.kristalose.com.
About Sancuso®(granisetron) Transdermal System
Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient's bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit www.sancuso.com.
About Vaprisol® (conivaptan hydrochloride) Injection
Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit www.vaprisol.com.
About Vibativ® (telavancin) for Injection
Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit www.vibativ.com.
ABOUT CUMBERLAND EMERGING TECHNOLOGIES:
Cumberland
CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products.
FORWARD LOOKING STATEMENTS:
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, tariffs, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the
|
Condensed Consolidated Balance Sheets (Unaudited) |
|||
|
|
|
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
Current assets: |
|
|
|
|
Cash and cash equivalents |
$ 16,087,281 |
|
$ 17,964,184 |
|
Accounts receivable, net |
10,316,911 |
|
11,701,466 |
|
Inventories, net |
3,222,872 |
|
3,999,995 |
|
Prepaid and other current assets |
1,578,265 |
|
2,786,513 |
|
Total current assets |
31,205,329 |
|
36,452,158 |
|
Non-current inventories |
9,526,122 |
|
11,005,499 |
|
Property and equipment, net |
297,793 |
|
277,365 |
|
Intangible assets, net |
15,988,232 |
|
17,973,449 |
|
|
914,000 |
|
914,000 |
|
Operating lease right-of-use assets |
7,125,408 |
|
6,176,923 |
|
Other assets |
2,850,265 |
|
2,784,016 |
|
Total assets |
$ 67,907,149 |
|
$ 75,583,410 |
|
LIABILITIES AND EQUITY |
|
|
|
|
Current liabilities: |
|
|
|
|
Accounts payable |
$ 13,446,531 |
|
$ 13,914,266 |
|
Operating lease current liabilities |
386,077 |
|
356,508 |
|
Current portion of revolving line of credit |
— |
|
5,100,000 |
|
Other current liabilities |
10,139,532 |
|
12,250,955 |
|
Total current liabilities |
23,972,140 |
|
31,621,729 |
|
Revolving line of credit - long term |
5,240,733 |
|
10,176,170 |
|
Operating lease non-current liabilities |
4,714,183 |
|
4,939,739 |
|
Other long-term liabilities |
6,301,166 |
|
6,299,795 |
|
Total liabilities |
40,228,222 |
|
53,037,433 |
|
Equity: |
|
|
|
|
Shareholders' equity: |
|
|
|
|
Common stock— no par value; 100,000,000 shares authorized; 14,959,937 |
51,441,398 |
|
46,821,425 |
|
Accumulated deficit |
(23,451,603) |
|
(23,967,931) |
|
Total shareholders' equity |
27,989,795 |
|
22,853,494 |
|
Noncontrolling interests |
(310,868) |
|
(307,517) |
|
Total equity |
27,678,927 |
|
22,545,977 |
|
Total liabilities and equity |
$ 67,907,149 |
|
$ 75,583,410 |
|
Condensed Consolidated Statements of Operations (Unaudited) |
|||||||
|
|
|
|
|
||||
|
|
Three months ended |
|
Six months ended |
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Net revenues |
$ 10,837,363 |
|
$ 9,848,849 |
|
$ 22,550,418 |
|
$ 18,346,550 |
|
Costs and expenses: |
|
|
|
|
|
|
|
|
Cost of products sold |
2,011,389 |
|
1,710,944 |
|
3,437,103 |
|
3,286,486 |
|
Selling and marketing |
4,223,647 |
|
4,248,401 |
|
8,455,627 |
|
8,402,989 |
|
Research and development |
1,468,399 |
|
1,059,187 |
|
2,763,475 |
|
2,217,440 |
|
General and administrative |
2,874,922 |
|
2,757,148 |
|
5,337,930 |
|
5,125,055 |
|
Amortization |
1,006,484 |
|
1,099,857 |
|
2,011,814 |
|
2,210,518 |
|
Total costs and expenses |
11,584,841 |
|
10,875,537 |
|
22,005,949 |
|
21,242,488 |
|
Operating income (loss) |
(747,478) |
|
(1,026,688) |
|
544,469 |
|
(2,895,938) |
|
Interest income |
127,489 |
|
61,841 |
|
253,198 |
|
158,587 |
|
Interest expense |
(109,547) |
|
(126,347) |
|
(273,349) |
|
(244,873) |
|
Income (loss) before income taxes |
(729,536) |
|
(1,091,194) |
|
524,318 |
|
(2,982,224) |
|
Income tax expense |
(5,671) |
|
(11,443) |
|
(11,341) |
|
(22,885) |
|
Net income (loss) |
(735,207) |
|
(1,102,637) |
|
512,977 |
|
(3,005,109) |
|
Net loss (income) at subsidiary attributable to |
(5,533) |
|
17,025 |
|
3,351 |
|
(26,766) |
|
Net income (loss) attributable to common |
$ (740,740) |
|
$ (1,085,612) |
|
$ 516,328 |
|
$ (3,031,875) |
|
Earnings (loss) per share attributable to common |
|
|
|
|
|
|
|
|
- basic |
$ (0.05) |
|
$ (0.08) |
|
$ 0.03 |
|
$ (0.21) |
|
- diluted |
$ (0.05) |
|
$ (0.08) |
|
$ 0.03 |
|
$ (0.21) |
|
Weighted-average shares outstanding |
|
|
|
|
|
|
|
|
- basic |
14,960,596 |
|
14,118,091 |
|
14,951,609 |
|
14,107,852 |
|
- diluted |
14,960,596 |
|
14,118,091 |
|
15,274,134 |
|
14,107,852 |
|
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|||
|
|
|
||
|
|
Six months ended |
||
|
|
2025 |
|
2024 |
|
Cash flows from operating activities: |
|
|
|
|
Net income (loss) |
$ 512,977 |
|
$ (3,005,109) |
|
Adjustments to reconcile net loss to net cash provided by operating activities: |
|
|
|
|
Depreciation and amortization expense |
2,065,502 |
|
2,290,130 |
|
Amortization of operating lease right-of-use assets |
570,369 |
|
570,369 |
|
Share-based compensation |
154,898 |
|
150,712 |
|
Increase (decrease) in non-cash contingent consideration |
83,578 |
|
(442,321) |
|
Increase in cash surrender value of life insurance policies over premiums |
(40,507) |
|
(101,538) |
|
Noncash interest expense |
10,723 |
|
8,654 |
|
Net changes in assets and liabilities affecting operating activities: |
|
|
|
|
Accounts receivable |
1,384,555 |
|
(1,861,587) |
|
Inventories, net |
1,818,196 |
|
1,243,245 |
|
Other current assets and other assets |
640,023 |
|
424,684 |
|
Operating lease liabilities |
(440,442) |
|
(429,064) |
|
Accounts payable and other current liabilities |
(2,018,925) |
|
(1,925,886) |
|
Other long-term liabilities |
1,371 |
|
85,404 |
|
Net cash provided by (used in) operating activities |
4,742,318 |
|
(2,992,307) |
|
Cash flows from investing activities: |
|
|
|
|
Additions to property and equipment |
(74,116) |
|
(48,799) |
|
Net investment in manufacturing |
(836,095) |
|
— |
|
Additions to intangible assets |
(32,111) |
|
(56,191) |
|
Net cash used in investing activities |
(942,322) |
|
(104,990) |
|
Cash flows from financing activities: |
|
|
|
|
Proceeds from ATM offering, net |
5,266,334 |
|
— |
|
Borrowings on line of credit |
— |
|
22,000,000 |
|
Payments on line of credit |
(10,035,437) |
|
(18,692,552) |
|
Cash settlement of contingent consideration |
(654,757) |
|
(813,478) |
|
Payments made in connection with repurchase of common shares |
(253,039) |
|
(381,851) |
|
Net cash (used in) provided by financing activities |
(5,676,899) |
|
2,112,119 |
|
Net decrease in cash and cash equivalents |
(1,876,903) |
|
(985,178) |
|
Cash and cash equivalents at beginning of period |
17,964,184 |
|
18,321,624 |
|
Cash and cash equivalents at end of period |
$ 16,087,281 |
|
$ 17,336,446 |
|
Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) |
||||||||
|
|
||||||||
|
(Unaudited) |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
Three months ended |
||||
|
|
|
2025 |
|
2025 |
|
2024 |
|
2024 |
|
|
|
Earnings |
|
Earnings per |
|
Earnings |
|
Earnings per |
|
Net loss attributable to common shareholders |
|
$ (740,740) |
|
$ (0.05) |
|
$ (1,085,612) |
|
$ (0.08) |
|
Less: Net (income) loss at subsidiary attributable to |
|
(5,533) |
|
— |
|
17,025 |
|
— |
|
Net loss |
|
(735,207) |
|
(0.05) |
|
(1,102,637) |
|
(0.08) |
|
Adjustments to net loss |
|
|
|
|
|
|
|
|
|
Income tax expense |
|
5,671 |
|
— |
|
11,443 |
|
— |
|
Depreciation and amortization |
|
1,033,918 |
|
0.07 |
|
1,139,445 |
|
0.08 |
|
Share-based compensation (a) |
|
80,686 |
|
0.01 |
|
71,958 |
|
0.01 |
|
Interest income |
|
(127,489) |
|
(0.01) |
|
(61,841) |
|
— |
|
Interest expense |
|
109,547 |
|
0.01 |
|
126,347 |
|
0.01 |
|
Adjusted earnings (loss) and adjusted diluted |
|
$ 367,126 |
|
$ 0.02 |
|
$ 184,715 |
|
$ 0.01 |
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted-average common shares outstanding: |
|
|
|
15,288,344 |
|
|
|
14,227,139 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended |
|
Six months ended |
||||
|
|
|
2025 |
|
2025 |
|
2024 |
|
2024 |
|
|
|
Earnings |
|
Earnings per |
|
Earnings |
|
Earnings per |
|
Net income (loss) attributable to common |
|
$ 516,328 |
|
$ 0.03 |
|
$ (3,031,875) |
|
$ (0.21) |
|
Less: Net (income) loss at subsidiary attributable to |
|
3,351 |
|
— |
|
(26,766) |
|
— |
|
Net Income (loss) |
|
512,977 |
|
0.03 |
|
(3,005,109) |
|
(0.21) |
|
Adjustments to net income (loss) |
|
|
|
|
|
|
|
|
|
Income tax expense |
|
11,341 |
|
— |
|
22,885 |
|
— |
|
Depreciation and amortization |
|
2,065,502 |
|
0.14 |
|
2,290,130 |
|
0.16 |
|
Share-based compensation (a) |
|
154,898 |
|
0.01 |
|
150,712 |
|
0.01 |
|
Interest income |
|
(253,198) |
|
(0.02) |
|
(158,587) |
|
(0.01) |
|
Interest expense |
|
273,349 |
|
0.02 |
|
244,873 |
|
0.02 |
|
Adjusted earnings (loss) and adjusted diluted |
|
$ 2,764,869 |
|
$ 0.18 |
|
$ (455,096) |
|
$ (0.03) |
|
|
|
|
|
|
|
|
|
|
|
Diluted weighted-average common shares outstanding: |
|
|
|
15,274,134 |
|
|
|
14,107,852 |
The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable
Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.
The Company defines these supplemental financial measures as follows:
- Adjusted Earnings (loss): Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense.
(a) Represents the share-based compensation of Cumberland.
- Adjusted Diluted Earnings (loss) Per Share: Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-23-revenue-growth-year-to-date-302522321.html
SOURCE
